


PRODUCT: GSK-1070916**ALTERNATE NAMES:** 3-[4-[4-[2-[3-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1-ethylpyrazol-3-yl]phenyl]-1,1-dimethylurea**CATALOG NUMBER:** B1939-5,25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C₃₀H₃₃N₇O**MOLECULAR WEIGHT:** 507.63**CAS NUMBER:** 942918-07-2**APPEARANCE:** Crystalline solid**SOLUBILITY:** DMSO (>25 mg/ml)**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20 °C. Protect from air and light**DESCRIPTION:** GSK-1070916 is a potent, reversible and ATP-competitive inhibitor of Aurora kinases B and C with IC₅₀ value of 3.5 nM and 6.5 nM, respectively. Treatment of GSK-1070916 suppresses cell proliferation in A549 human lung cancer cells with EC₅₀ value of 7 nM.**REFERENCES:** Adams, N.D., *et al.* (2010). *J. Med. Chem.* **53**, 3973-4001.**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

AT-9823 (Cat. No. 2432-5, 25)

Aurora Kinase B Inhibitor (Cat. No. 1583-5, 25)

AZD1480 (Cat. No. 2315-1, 5)

CCT-129202 (Cat. No. B1934-5,25)

CCT-137690 (Cat. No. B1935-5,25)

CP-690550 (Cat. No. 1622-5, 25)

CYC-116 (Cat. No. B1936-5,25)

Danusertib (Cat. No. B1937-5,25)

ENMD-2076 (Cat. No. B1938-5,25)

GSK-1070916 (Cat. No. B1939-5,25)

Lestaurtinib (Cat. No. 1805-500, 1000)

MLN8237 (Cat. No. 2718-5,25)

LLL12 (Cat. No. 1792-5, 25)

MS-1020 (Cat. No. 1911-1)

PF-03814735 (Cat. No. B1257-1,5)

Reversine (Cat. No. 1851-1, 5)

Ruxolitinib, free base (Cat. No. 2139-5, 25)

Tozasertib (Cat. No. 1595-25, 100)

EZSolution™ Tozasertib (Cat. No. 1803-

TC-S 7010 (Cat. No. B1203-5,25)

TG101348 (Cat. No. 2314-1, 5)

Tyrphostin AG 490 (Cat. No. 1570-5)

WHI-P131 (Cat. No. 1853-5, 25)

WP1066 (Cat. No. 1809-5, 25)

USAGE: **FOR RESEARCH USE ONLY! Not to be used in humans**